Pictured from left: Sneha Phadke, DO, University of Iowa, co-investigator of BTCRC-BRE18-337; Oana Danciu, MD, University of Illinois at Chicago, sponsor-investigator of BTCRC-BRE15-016; Kari Wisinski, MD, University of Wisconsin, sponsor-investigator of BTCRC-BRE18-337 and co-investigator of BTCRC-BRE15-016.
Big Ten cancer researchers presented two Big Ten Cancer Research Consortium (Big Ten CRC) studies during the 2019 San Antonio Breast Cancer Symposium in December.
In a poster session, investigators reported on safety results from BTCRC-BRE15-016, a phase 2 study of palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. Researchers concluded the combination of palbociclib and tamoxifen was well tolerated with expected toxicities, and neutropenia was the most frequently reported adverse event. Researchers noted this is one of the first trials to assess the safety of the combination of palbociclib with tamoxifen in metastatic hormone receptor positive breast cancer and has implications for the early stage setting. See abstract.
Jan. 7, 2020:Investigator Spotlight: Benjamin Teply, MD, University of Nebraska Medical Center Research interests: I am a medical oncologist engaged in clinical and translational research in genitourinary malignancies, with a special focus in prostate cancer. I have worked on novel treatment strategies for prostate cancer, with a focus on mechanisms other than suppression of androgen signaling, in both treatment-naïve (such as PARP inhibition) and castration-resistant prostate cancer (such as therapeutic high-dose testosterone). I am also dedicated in optimizing the use of approved therapies to maximize patient benefit. Read More
Dec. 3, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) congratulates researchers who recently received grants to continue their work to fight against cancer. We also zoom in on the work researchers are doing to understand and treat breast cancer both during and after surgery and/or treatment. Read More
Nov. 13, 2019: H. Rex Gaskins, PhD, associate director for education at the Cancer Center at Illinois (CCIL) and Keith W. and Sarah M. Kelly Professor of Immunophysiology at University of Illinois at Urbana-Champaign, has been appointed to represent the university on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. As a collaboration among Big Ten universities, the Big Ten CRC leverages the scientific and clinical expertise of its members by developing and conducting early phase oncology clinical trials. In 2018, CCIL established itself as a research institute on the Urbana-Champaign campus... Read More
Oct. 31, 2019: Applications are now open for a nationwide integrative oncology training program. The Integrative Oncology Scholars Program at the University of Michigan is funded by a National Cancer Institute R25 grant. It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Read More
Oct. 10, 2019: Investigators from Big Ten Cancer Research Consortium (Big Ten CRC) member institutions gathered at Big Ten Conference Headquarters in Chicago for the consortium’s annual summit, September 21. The 2019 Summit, hosted by the University of Iowa Holden Comprehensive Cancer Center, featured topics presented by Big Ten investigators and industry representatives, and opportunities to discuss current and potential collaborations. Read More
Oct. 1, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) welcomes members to new leadership roles. We also highlight some of the work universities are doing to support cancer survivors and increase their quality of life after cancer, while researchers continue to explore novel approaches to improve survival and prevent relapses. Read More
Sept. 25, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a wide range of topics from newly activated Big Ten CRC studies, research with cancer and genomics, rare cancers, and developing new strategies to integrate patient education in regular cancer care visits. Read More
Sept. 18, 2019: Muhammad Furqan, MD, a medical oncologist and clinical associate professor of internal medicine – Hematology, Oncology and Blood and Marrow Transplantation at the University of Iowa Carver College of Medicine, will represent the university on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. As a collaboration of Big Ten universities, the Big Ten CRC leverages the scientific and clinical expertise of its members by developing and conducting early-phase oncology clinical trials that can provide access to novel treatments to patients with cancer. Dr. Furqan specializes in lung cancer and leads the thoracic multidisciplinary oncology group at the Read More
Sept. 16, 2019: Every year, selected junior investigators learn how to design effective clinical trials for therapeutic interventions in treating cancer during an intensive week-long workshop hosted jointly by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). The conference, known in oncology circles as the “Vail Workshop,” is held in Vail, Colo. and is an ideal backdrop for clinical and research oncologists to unplug, network, and gain valuable feedback from leading investigators in oncology in a retreat-like setting. “For junior investigators, the Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube